2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
142
Gastrointestinal Stromal Tumors
71
Leukemia
69
Leukemia, Myeloid, Chronic-Phase
50
Precursor Cell Lymphoblastic Leukemia-Lymphoma
43
Blast Crisis
22
Neoplasms
15
Brain Neoplasms
15
Philadelphia Chromosome
14
Melanoma
13
Sarcoma
12
Neoplasm Metastasis
12
Leukemia, Myeloid, Acute
12
Leukemia, Myeloid, Accelerated Phase
12
Glioblastoma
12
Lung Neoplasms
11
Prostatic Neoplasms
10
Leukemia, Myeloid
9
Gliosarcoma
9
Glioma
8
Breast Neoplasms
8
Primary Myelofibrosis
7
Leukemia, Myelomonocytic, Chronic
7
Central Nervous System Neoplasms
7
Astrocytoma
7
Recurrence
6
Polycythemia Vera
6
Ovarian Neoplasms
6
Oligodendroglioma
6
Myeloproliferative Disorders
6
Interventions
Amifostine
19
Cisplatin
15
Radiotherapy
13
Etoposide
10
Cyclophosphamide
9
Carboplatin
8
Paclitaxel
7
Filgrastim
7
Drug Therapy
5
Cytarabine
5
apatinib
4
Methotrexate
4
sodium thiosulfate
3
Methylprednisolone
3
Gemcitabine
3
Docetaxel
3
sargramostim
2
pegfilgrastim
2
glucarpidase
2
etoposide phosphate
2
denileukin diftitox
2
camrelizumab
2
Voriconazole
2
Vincristine
2
Social Determinants of Health
2
Pyridoxine
2
Peripheral Blood Stem Cell Transplantation
2
Nivolumab
2
Mitoxantrone
2
Melphalan
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Drug-Related Side Effects and Adverse Reactions
×
Imatinib Mesylate
×
Clear all
NCT04138381
2023-03-27
SeliGIST
Grupo Espanol de Investigacion en Sarcomas
Phase 1/2
Unknown
30 enrolled